Observation of terlipressin with retention-enema of traditional Chinese drug in management of patients with hepatorenal syndrome

Chen WeiHua; Li WenYong; Deng DaiFu

Issue 5

May 2008

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2008 > 24(5): 351-353

PDF( 114 KB)

特利加压素联合中药泻心汤保留灌肠治疗肝硬化肝肾综合征的疗效观察

Published Date: 2008-05-20

Abstract

Abstract

Objective To observe the effect of terlipressin with retention-enema of traditional Chinese drug-xiexin docoction in management of patients with hepatorenal syndrome.Methods 26 patients were divided into two groups, terlipressin with retention-enema of traditional Chinese drug-xiexin decoction were used in the treating group, while in the control group the dopamine and large-dose of lasix were administered.The clinical symptoms, total urine output, serum creatinine, BUN, liver function and ascites were observed during treatment.Results In the treating group, the total urine output was increased significantly;the serum creatinine、BUN and blood amonia were descended;the liver function was better than before.However there weren't obviously improvement in the control group.Conclusion Because the hemodynamics were changed by the terlipressin and the endotoxin was reduced by retention-enema of traditional Chinese drug, terlipressin with retention-enema of traditional Chinese drug-xiexin docoction can get enhanced results.
- hepatorenal syndrome,
- terlipressin,
- traditional chinese drug,
- liver cirrhosis

FullText(HTML)

References(10)

References

[1]Gines A, Ecorsell A, Gines P, et al.Incidence, predicitive factorsand prognosis of the hepatorenal syndrome in cirrhosis withascites[J].Gastroenterology, 1993, 105 (1) ∶229-230.

[2]孙静媛, 兰孟冬.内毒素对肝硬化及重型肝炎各种并发症和预后的影响[J].河北医学, 2001, 7 (10) ∶878-880.

[3]Arroyo V, Gines P, Gerbes A, et al.Definition and diagnostic crite-ria of refractory ascites and hepatorenal syndrome in cirhosis.Interna-tional Ascites clubs[J].Hepatology, 1996, 23 (1) ∶164-173.

[4]Schrier RW, Arroyo V, Bermardi M, et al.Pcriphcral artcrial vaso-dilatation hypothesis:a proposal for the initiation of renal sldium andwater retention on cirrhosis[J].Hepatology, 1998, 8 (5) ∶1151-1157.

[5] 梁扩寰, 李绍白.肝脏病学[M].第二版.北京:人民卫生出版社, 2006∶522-524, 541-557.

[6]孙波, 慎睿哲, 关云林, 等.血管活性药物治疗肝肾综合征[J].胃肠病学, 2005, 10 (2) ∶127-128.

[7]熊玉霞, 孟宪丽, 张艺, 等.泻心汤及其拆方抗内毒素作用研究[J].中药药理与临床, 2007, 23 (1) ∶7-8.

[8]武希润, 郭文栋, 马学惠, 等.大黄对暴发性肝衰竭肝损伤及肝再生的影响[J].中华肝脏, 1999, 7 (3) ∶179.

[9]何冬宁, 徐锡坤, 许娟华, 等.牡蛎提取营养液对大剂量CCl4致小鼠急性肝损伤的保护作用[J].中国公共卫生学报, 1997, 16 (3) ∶152-153.

[10]嵇扬, 靳守东, 刘云, 等.牡蛎水提取液对小鼠腹腔巨噬细胞释放一氧化氮的影响[J].中医药学报, 2001, 29 (3) ∶62-63.

Relative Articles

[1]	Hepatobiliary Study Group of Chinese Society of Gastroenterology of Chinese Medical Association, Hepatology Committee of Chinese Research Hospital Association. Practice guidance for the use of terlipressin for liver cirrhosis related complications (2021)[J]. Journal of Clinical Hepatology, 2022, 38(8): 1733-1738. doi: 10.3969/j.issn.1001-5256.2022.08.006
[2]	Qianmei CAO, Zhechuan MEI. Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(10): 2439-2443. doi: 10.3969/j.issn.1001-5256.2021.10.038
[3]	LIAO XianHua, YE JunZhao, ZHONG BiHui. Pathogenesis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2406-2410. doi: 10.3969/j.issn.1001-5256.2020.11.002
[4]	Li XiaoLu, Ding HuiGuo, Ceng AJuan, Lu: XinYue, Li Lei. Clinical effect of terlipressin combined with somatostatin in treatment of esophagogastric variceal bleeding with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(6): 1273-1277. doi: 10.3969/j.issn.1001-5256.2020.06.017
[5]	Li XiaoLu, Li Lei. Application of terlipressin in the treatment of esophagogastric variceal bleeding in liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2308-2311. doi: 10.3969/j.issn.1001-5256.2019.10.038
[6]	Tan YanXin, Long FuLi, Mao DeWen, Zhang JianLing, Ma YuZhen, Yan LianJie. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2266-2271. doi: 10.3969/j.issn.1001-5256.2019.10.027
[7]	Feng QingLing, Feng ZeMin, Zhang ChunQing, Wang GuangChuan, Feng Hua. Effects of terlipressin and double- dose octreotide on hepatic venous pressure gradient in patients with liver cirrhosis:a comparative study[J]. Journal of Clinical Hepatology, 2016, 32(4): 720-723. doi: 10.3969/j.issn.1001-5256.2016.04.022
[8]	Xia YuLian, Zhang ChunQing, Wang GuangChuan, Feng Hua, Zhang MingYan. Individual and combined effects of octreotide and terlipressin on hepatic venous pressure gradient in cirrhotic patients[J]. Journal of Clinical Hepatology, 2015, 31(2): 214-218. doi: 10.3969/j.issn.1001-5256.2015.02.017
[9]	Ding XiaoHong, Gu JianYing. Clinical efficacy of terlipressin in treatment of type II hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2015, 31(5): 745-748. doi: 10.3969/j.issn.1001-5256.2015.05.027
[10]	Zhan GuoQing, Li Fang, Li RuGui, Guo Peng, Liu Xiang, Zhang WeiWei, Tan HuaBing. Efficacy of terlipressin therapy for refractory ascites in cirrhosis and type-2 hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2015, 31(8): 1287-1290. doi: 10.3969/j.issn.1001-5256.2015.08.025
[11]	Gao BaoXiu, Nie Xin, He Yong, Yang ZhengBing, Luo TongXing, Song HaoLan, Li GuiXing. Analysis of endotoxin and endothelin-1 levels in patients with type 1 hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2014, 30(1): 58-61. doi: 10.3969/j.issn.1001-5256.2014.01.016
[12]	Chen Si, Sun ZhangYu, Zhang ZhiHao, Wang YingYing. Therapeutic effect of terlipressin combined with albumin in 24 patients with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2014, 30(8): 782-784. doi: 10.3969/j.issn.1001-5256.2014.08.021
[13]	Zheng XiaoLi, Wang LiangZhi, He JianHua, Xiang XingChao, Zhou XiangYu. Diagnostic value of serum cystatin C and urotensin II for hepatorenal syndrome in patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(8): 627-630. doi: 10.3969/j.issn.1001-5256.2013.08.019
[14]	Gao BaoXiu, Nie Xin, Wu Bin, He Yong, Song HaoLan, Luo TongXing, Xu Jing, Li GuiXing. Implications of elevated levels of prostaglandin I2 and thromboxane A2 in type I hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2012, 28(11): 860-862.
[15]	Wang JiYao. The difficulties in diagnosis and treatment of hepatorenal syndrome-raised by clinical cases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1019-1021.
[16]	Xu XiaoYuan, Zheng YingYing. Hepatorenal syndrome-vasoconstrictor or vasodilator?[J]. Journal of Clinical Hepatology, 2011, 27(8): 801-803+817.
[17]	Xie YongPeng, Hou Yue, Zang XiuXian, Chu Zhe. The development of treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(5): 558-561.
[18]	Zheng XiaoLi, Wang LiangZhi. Current diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(1): 107-109.
[19]	Fu Qiang, Tang TongYu. Advance in research of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2010, 26(5): 557-560.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2176) PDF downloads(734)

特利加压素联合中药泻心汤保留灌肠治疗肝硬化肝肾综合征的疗效观察

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

特利加压素联合中药泻心汤保留灌肠治疗肝硬化肝肾综合征的疗效观察

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content